The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Ipilimumab and nivolumab (I+N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.

Jennifer  Allison

No Relationships to Disclose

Richard  Griffiths

No Relationships to Disclose

Tom  Waddell

Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche

Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen

Manon Rhys  Pillai

No Relationships to Disclose